Burden of disease in adult patients with hypophosphatasia: Results from two patient-reported surveys.

Journal Article

Hypophosphatasia (HPP) is a rare metabolic bone disease caused by loss-of-function mutation(s) in the tissue-nonspecific alkaline (TNSALP) phosphatase gene, which manifests as rickets and/or osteomalacia with systemic complications and affects patients of all ages. The burden of disease is poorly characterized in adult patients.We assessed patient-reported burden of disease using two surveys reasonably specific for HPP symptomatology, the Hypophosphatasia Impact Patient Survey (HIPS) and the Hypophosphatasia Outcomes Study Telephone interview (HOST).Patients with HPP were invited to participate via patient advocacy groups or their medical provider. Survey questions captured demography, HPP-related medical history, mobility, and health-related quality of life (using Short Form 12 [version 2] Health Survey [SF-12v2]) via internet report (HIPS) or telephone interview (HOST).One hundred twenty-five adults responded (mean [standard deviation, SD] age: 45 [14.3] years). Eighty-four patients (67%) reported pediatric-onset of their symptoms. Common clinical features in the study population included pain (95% of patients), fractures (86% of patients) muscle weakness (62%) and unusual gait (52%). Use of assistive devices for mobility (60%) was also prevalent. Twenty-six percent of patients reported more than 10 fractures. Seventy-four percent of patients had undergone orthopedic/dental surgical procedures. The health profile of patients responding on the SF-12 showed a broad and substantial impact of HPP on health-related quality of life, with domains related to physical ability showing the greatest decrement compared to normative data.In aggregate, these data indicate that HPP can confer a high burden of illness in adulthood.

Full Text

Duke Authors

Cited Authors

  • Weber, TJ; Sawyer, EK; Moseley, S; Odrljin, T; Kishnani, PS

Published Date

  • October 2016

Published In

Volume / Issue

  • 65 / 10

Start / End Page

  • 1522 - 1530

PubMed ID

  • 27621187

Electronic International Standard Serial Number (EISSN)

  • 1532-8600

International Standard Serial Number (ISSN)

  • 0026-0495

Digital Object Identifier (DOI)

  • 10.1016/j.metabol.2016.07.006

Language

  • eng